- The U.K.'s Medicines and Healthcare Products Regulatory Agency (MHRA) has accepted for review Humanigen Inc's HGEN marketing application seeking approval for lenzilumab in COVID-19.
- MHRA has accepted the application under expedited COVID-related rolling review, with assessment expected to occur more rapidly than a standard rolling review.
- Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF).
- GM-CSF is an upstream regulator of many inflammatory cytokines and chemokines involved in the cytokine storm.
- Price Action: HGEN shares are up 1.68% at $16.93 during the market session on the last check Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
